Opinion|Videos|August 8, 2024

Intro and Welcomes

Author(s)Gordon Lam, MD, Leonard Calabrese, DO, Grace Wright, MD, PhD

A panel of medical experts introduce themselves before diving into a discussion about remission achievement in rheumatoid arthritis.

Episodes in this series

EP. 1 Intro and Welcomes

EP. 1 Intro and Welcomes

EP. 2 Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP. 2 Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP. 3 Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP. 3 Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP. 4 Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP. 4 Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP. 5 Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP. 5 Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP. 6 Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP. 6 Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP. 7 Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP. 7 Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP. 8 Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

EP. 8 Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

EP. 9 Advanced Treatment Options for RA: Exploring the Data

EP. 9 Advanced Treatment Options for RA: Exploring the Data

EP. 10 Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP. 10 Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP. 11 JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP. 11 JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP. 12 JAK Inhibitor Selectivity and Dose-Related Toxicity

EP. 12 JAK Inhibitor Selectivity and Dose-Related Toxicity

EP. 13 Outcomes of Class Switching vs Cycling TNF Inhibitors

EP. 13 Outcomes of Class Switching vs Cycling TNF Inhibitors

EP. 14 Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices

EP. 14 Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices

EP. 15 Safety and Efficacy of Janus Kinase Inhibitors

EP. 15 Safety and Efficacy of Janus Kinase Inhibitors

EP. 16 Closing Remarks

EP. 16 Closing Remarks

Related Content

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis

ByVictoria Johnson

January 14th 2026

Susan Manzi, MD, MPH Credit: Allegheny Health Network

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus

ByChelsie Derman

January 14th 2026

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

ByRosalind Ramsey-Goldman, MD

January 13th 2026

Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control

Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control

ByVictoria Johnson

January 12th 2026

5 Rheumatology Headlines You Missed in December 2025

5 Rheumatology Headlines You Missed in December 2025

ByVictoria Johnson

January 9th 2026